Abivax says Scorpion Capital report contains inaccurate, misleading claims
ABVX•Abivax disputed claims in Scorpion Capital’s November 20, 2026, report and reaffirmed confidence in Phase 3 ABTECT results supporting a U.S. FDA new drug application filing by year-end.
1. Company disputes report
Abivax called numerous statements in Scorpion Capital’s report inaccurate or misleading and reaffirmed confidence in Phase 3 ABTECT results supporting a U.S. FDA new drug application filing by year-end. Scorpion disclosed a short position and plans to cover a substantial portion upon publication, Abivax said; the company is reviewing the report and expects to provide further updates.




